Clinical Trial Results The clinical trial SURMOUNT-5 (NCT05822830) of adults with obesity who did not have type 2 diabetes demonstrated that Zepbound patients had an average weight loss of 50.3 lbs (22.8 kg), which was 20.2% of their body weight, and a 7.2-inch ( 18.4 cm) reduction in waist circumference, at 72 weeks
For complete information about potential drug interactions, consult the Prescribing Information in Canada: and discuss any concerns with your healthcare provider
c) based on animal studies rather than human ones
Severe cases can progress to founder, where the coffin bone rotates or sinks, resulting in long-term soundness issues and permanent hoof damage
What Is Semaglutide & How Does It Work
Limited Range of Motion: Reduced flexibility and range of motion in affected joints can hinder daily activities like bending, reaching, or walking